Last updated: February 23, 2026
What is NDC 50474-0802?
NDC 50474-0802 refers to a specific pharmaceutical product. Based on available data, it corresponds to Tremezzo (Tremelimumab), a monoclonal antibody developed by various biopharmaceutical companies for cancer immunotherapy. As the NDC code indicates, the drug is a biologic payable in oncology indications.
Market Overview
Therapeutic Area and Competitive Landscape
Tremelimumab is an anti-CTLA-4 monoclonal antibody designed to boost immune response against tumors. Its primary clinical applications include:
- Melanoma
- Non-small cell lung carcinoma (NSCLC)
- Other solid tumors under investigation
The immunotherapy segment for oncology holds a high growth rate, driven by breakthroughs in checkpoint inhibitors and expanding indications.
Major competitors include:
- Ipilimumab (Yervoy)
- Cemiplimab (Libtayo)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
Market Size and Adoption Factors
Estimations of the global market for checkpoint inhibitors surpass $25 billion in 2022, with growth forecasted at a compounded rate of 11% through 2027.[1] Tremelimumab's market share remains limited due to:
- Pending regulatory approvals
- Pricing strategies
- Commercialization collaborations
- Positive or negative trial outcomes
The drug's adoption depends heavily on clinical trial success and regulatory clearance in key regions, notably US, EU, and China.
Price Analysis
Current Pricing Landscape
As a biologic, NDC 50474-0802's list price exerts substantial influence on market penetration. Similar products are priced as follows:
| Drug |
Indication |
Approximate Annual Cost |
Approval Status |
| Ipilimumab |
Melanoma |
$150,000 |
FDA approved |
| Cemiplimab |
Cutaneous carcinoma |
$140,000 |
FDA approved |
| Nivolumab |
Multiple cancers |
$150,000 |
FDA approved |
| Pembrolizumab |
Multiple cancers |
$155,000 |
FDA approved |
Note: Prices are estimates based on US list prices as of 2022.
Factors Affecting Pricing
- Manufacturing complexity of biologics restricts price reductions.
- Market exclusivity offers pricing power for initial years post-approval.
- Payer negotiations influence actual reimbursed prices.
- Therapy duration impacts total treatment costs.
Projected Pricing Trends
Over the next five years, biologic prices for immunotherapies are projected to decline only marginally, at a compounded rate of 1-2% annually, due to patent protections and manufacturing costs.
Pricing forecasts indicate:
- A stabilized average annual cost for NDC 50474-0802 between $140,000 and $150,000.
- Opportunities for discounts ranging from 10-30% in commercial markets through negotiations and value-based agreements.
Market Entry and Revenue Potential
Regulatory Timeline
- Limited phase trials are ongoing or completed, with regulatory approval anticipated within 1-3 years depending on trial success.
- US FDA and EMA approvals are critical for rapid market expansion.
Revenue Projections
Assuming approval in 2024, potential revenues depend on:
- Patient eligibility: Estimated 10,000 patients annually in the US for melanoma, growing with indications expansion.
- Market penetration: Targeting 20-30% within the first three years.
- Pricing: maintenance of $145,000 per treatment course.
| Year |
Estimated Patients |
Market Share |
Revenue Estimate |
| 2024 |
2,000 |
10% |
~$290 million |
| 2025 |
4,000 |
20% |
~$580 million |
| 2026 |
6,000 |
30% |
~$870 million |
Revenue projections increase sharply with indication approvals and expanded clinical acceptance.
Risks and Opportunities
Risks
- Clinical trial failures impede market entry.
- Competitive products may be priced more aggressively.
- Regulatory delays extend time-to-market.
Opportunities
- Expansion into additional indications.
- Strategic alliances for manufacturing and distribution.
- Price premium from combination therapies or predictive biomarkers.
Key Takeaways
- NDC 50474-0802 (Tremelimumab) exists in a competitive and rapidly expanding immunotherapy market.
- Current biologic prices hover around $140,000-$150,000 annually.
- Market penetration is limited but forecasted to grow significantly with regulatory approvals.
- Revenue could reach hundreds of millions to over a billion dollars within the first five years post-approval, contingent on clinical success and market strategy.
- Price sustainability is under risk from competitive pressures and reimbursement negotiations.
FAQs
Q1: What are the main competitors to NDC 50474-0802?
Ipilimumab and cemiplimab are primary competitors, with established presence in immuno-oncology.
Q2: How does the price compare to similar biologics?
Prices are similar, generally $140,000-$155,000 annually, reflecting manufacturing costs and market exclusivity.
Q3: What factors influence future pricing?
Regulatory approval, clinical efficacy, payer negotiations, and manufacturing efficiencies.
Q4: When is commercialization expected?
Regulatory approval is likely within 1-3 years, depending on trial outcomes.
Q5: What is the potential market size?
In the US, approximately 10,000 melanoma patients annually, with broader indications increasing total addressable market.
References
[1] Market Research Future. (2022). Global checkpoint inhibitors market analysis. Retrieved from https://www.marketresearchfuture.com
